Keymed Biosciences Balance Sheet Health
Financial Health criteria checks 4/6
Keymed Biosciences has a total shareholder equity of CN¥2.6B and total debt of CN¥719.5M, which brings its debt-to-equity ratio to 27.3%. Its total assets and total liabilities are CN¥3.8B and CN¥1.2B respectively.
Key information
27.3%
Debt to equity ratio
CN¥719.55m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥2.58b |
| Equity | CN¥2.64b |
| Total liabilities | CN¥1.17b |
| Total assets | CN¥3.81b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 64Z's short term assets (CN¥2.8B) exceed its short term liabilities (CN¥559.7M).
Long Term Liabilities: 64Z's short term assets (CN¥2.8B) exceed its long term liabilities (CN¥608.6M).
Debt to Equity History and Analysis
Debt Level: 64Z has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 64Z's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 64Z has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 64Z has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.